Top 50 Biotech Angel Investors in United Kingdom (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Jonathan Milner
Angel
|
30 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Nadav Rosenberg
Angel
|
5 | United Kingdom, France, Israel | Seed, Pre-Seed, Series A | Biotechnology, Artificial Intelligence, Software | $850k–$19M |
|
Paul Wicks
Angel
|
3 | United Kingdom, United States, Japan | Seed, Pre-Seed, Series A | Software, Wellness, E-Commerce | $539k–$11M |
|
Darrin Disley
Angel
|
3 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Big Data | $458k–$3.7M |
|
Bradley Horowitz
Angel
|
3 | United States, United Kingdom, Germany | Seed, Series A, Series B | Software, Information Technology, Artificial Intelligence | $150k–$120M |
|
Milad Alucozai
Angel
|
3 | United States, Canada, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Medical | $110k–$55M |
|
Ian Hogarth
Angel
|
3 | United Kingdom, United States, Germany | Seed, Series A, Pre-Seed | Software, E-Commerce, Artificial Intelligence | $668k–$28M |
|
Jude Gomila
Angel
|
3 | United States, United Kingdom, Canada | Seed, Pre-Seed, Angel | Software, Biotechnology, Information Technology | $190k–$4.7M |
|
Stefano Bernardi
Angel
|
3 | Italy, United Kingdom, France | Seed, Pre-Seed | Software, Biotechnology, Artificial Intelligence | $100k–$45M |
|
DrPano Kroko Churchill
Angel
|
3 | United Kingdom | Angel, Series A | Health Care, Therapeutics, Biotechnology | $150k–$458k |
|
Charlie Songhurst
Angel
|
3 | United Kingdom, United States, Germany | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $510k–$6.8M |
|
Peder Nielsen
Angel
|
3 | United Kingdom | Seed, Convertible Note | Biotechnology, Machine Learning | |
|
Jeff Dean
Angel
|
3 | United States, United Kingdom, Japan | Seed, Series A, Pre-Seed | Artificial Intelligence, Information Technology, Software | $450k–$53M |
|
Serge Chiaramonte
Angel
|
2 | United Kingdom, United States, France | Seed, Pre-Seed | FinTech, Financial Services, Information Technology | $637k–$38M |
|
Pratima Aiyagari
Angel
|
2 | United Kingdom, France, Croatia | Seed, Pre-Seed, Series A | Analytics, Cyber Security, SaaS | $982k–$12M |
|
Jon Oringer
Angel
|
2 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Information Technology, Health Care | $100k–$31M |
|
Nadav Ben-Chanoch
Angel
|
2 | United States, United Kingdom, France | Seed, Pre-Seed | Software, Information Technology, Health Care | $125k–$5.5M |
|
Aidan Gomez
Angel
|
2 | United States, United Kingdom, Canada | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, Information Technology | $1.8M–$12M |
|
Mark Evans
Angel
|
2 | United Kingdom, United States, The Netherlands | Series A, Seed, Series C | Software, E-Commerce, Health Care | $1.4M–$24M |
|
Gilad Engel
Angel
|
2 | France, Israel, United Kingdom | Seed, Pre-Seed | Hardware, Analytics, Biotechnology | $1.2M–$1.9M |
|
Hugh Grant
Angel
|
2 | United Kingdom | Seed | Biotechnology, Machine Learning | |
|
Nick Boyle
Angel
|
2 | United Kingdom | Seed | Biofuel, Agriculture, Artificial Intelligence | $3M–$3M |
|
Patrick Pichette
Angel
|
2 | United Kingdom, Germany, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $750k–$95M |
|
Jim Mellon
Angel
|
2 | United States, United Kingdom, Germany | Series A, Seed | Biotechnology, Food and Beverage, Health Care | |
|
Amar Shah
Angel
|
2 | United Kingdom, Poland, Germany | Pre-Seed, Seed, Angel | Artificial Intelligence, Software, Health Care | $642k–$15M |
|
Paul Forster
Angel
|
2 | United Kingdom, Germany, United States | Seed, Series A, Pre-Seed | Software, FinTech, Financial Services | $1.1M–$15M |
|
Tim Dempsey
Angel
|
2 | United Kingdom | Seed, Series A | Software, SaaS, Financial Services | $962k–$2.5M |
|
Chris Mairs
Angel
|
2 | United Kingdom, United States | Seed, Pre-Seed, Angel | Software, FinTech, Financial Services | $334k–$3.9M |
|
Ed Parkinson
Angel
|
2 | United Kingdom | Seed | Software, Health Care, Life Science | $1.8M–$3.3M |
|
Edward Lando
Angel
|
2 | United States, France, United Kingdom | Seed, Pre-Seed | Software, Health Care, Information Technology | $125k–$6.6M |
|
Inaki Berenguer
Angel
|
2 | Spain, United States, United Kingdom | Seed, Angel, Pre-Seed | FinTech, E-Commerce, Financial Services | $233k–$8.5M |
|
Ariel Poler
Angel
|
2 | United States, Spain, Mexico | Seed, Series A, Angel | Software, Social Media, Internet | $455k–$7.9M |
|
Mati Staniszewski
Angel
|
2 | United States, United Kingdom, Poland | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, SaaS | $2M–$40M |
|
Robert Kopple
Angel
|
2 | United States, United Kingdom | Convertible Note | FinTech, Finance, Life Science | |
|
Damien Lane
Angel
|
2 | United Kingdom, United States, Ireland | Seed, Pre-Seed, Series A | SaaS, Software, Health Care | $459k–$16M |
|
Oliver Sexton
Angel
|
1 | United Kingdom | Seed, Pre-Seed | Biotechnology, Health Care, AgTech | |
|
Jim Warwick
Angel
|
1 | United Kingdom | Seed | Life Science, Biotechnology | |
|
Siddhant Jayakumar
Angel
|
1 | United Kingdom | Pre-Seed | Biotechnology, Public Safety, Artificial Intelligence | |
|
Andrew J M Richards
Angel
|
1 | United Kingdom | Post-IPO Equity | Biopharma, Education, Biotechnology | |
|
Jan Hruska
Angel
|
1 | United Kingdom | Seed | Medical, Health Care, Life Science | |
|
Nicholas Edwards
Angel
|
1 | United Kingdom | Seed | Medical, Health Care, Life Science | |
|
Margaret Georgiadis
Angel
|
1 | United States, United Kingdom | Seed, Series A, Series B | Health Care, Apps, Wellness | |
|
Silla Scheepens
Angel
|
1 | United Kingdom | Seed | Biotechnology, Food Processing, Food and Beverage | |
|
Fiona Pathiraja
Angel
|
1 | United Kingdom, Germany, Armenia | Seed, Pre-Seed, Series A | Health Care, Science/Engineering, Software | |
|
Declan Doogan
Angel
|
1 | United States, United Kingdom | Seed, Series A | Health Care, Biotechnology, Science/Engineering | |
|
Ahmed Medhat
Angel
|
1 | United States, United Kingdom | Seed, Pre-Seed | Artificial Intelligence, Information Technology, Machine Learning | |
|
Chris Paul
Angel
|
1 | United States, France, Portugal | Seed, Series A | Food and Beverage, Sports, Health Care | |
|
Marcus East
Angel
|
1 | United Kingdom | Seed | Software, Health Care, Biotechnology | |
|
Sam Fazeli
Angel
|
1 | United Kingdom | Post-IPO Equity | Education, Health Care, Biotechnology | |
|
Johnathan Matlock
Angel
|
1 | United Kingdom | Seed, Pre-Seed | Biotechnology, Medical, Health Care | |
| Access all 50 angel investors in United Kingdom Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 61
- Round size: Seed $537k–$16M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Israel
Investor stats
- Total investments: 15
- Round size: Seed $850k–$3.1M; Pre-Seed $2M–$2M; Series A $18M–$19M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
- thymia — We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient.
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Paul Wicks, Ph.D., is a strategic advisor and independent consultant who helps digital health and life science companies turn data into evidence, evidence into influence, and influence into impact. He has supported over 40 organizations including AstraZeneca, Ada Health, Biogen, Click Therapeutics, and Woebot.Previously, Paul spent 13 years as VPof R&D at PatientsLikeMe, building one of the world’s largest patient communities and pioneering decentralized trials, digital biomarkers, and real-world evidence. He has authored over 200 peer-reviewed papers and served on editorial boards of journals including the BMJ, Digital Biomarkers, and BMC Medicine.A neuropsychologist by training, Paul completed his Ph.D. at King’s College London and a postdoc on the psychology of Parkinson’s disease. His work has been featured by BBC, CNN, and The New York Times. He was named MIT Technology Review’s “Humanitarian of the Year” in 2011 and is a TED Fellow and FLIER alumnus of the Academy of Medical Sciences. He is an honorary Professor at the University of Birmingham.
Show more...Investment focus
- Industry: Software, Wellness, E-Commerce
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 17
- Round size: Seed $3M–$6.6M; Pre-Seed $539k–$1M; Series A $6.9M–$11M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Epiminds — Epiminds develops multi-agent AI systems to run marketing end-to-end.
- Run Yourself — RunYourself is a prompt-driven, AI-assisted platform making it easy for managers to have effective coaching conversations. We blend expert coaching prompts on a spectrum of crucial topics with AI-powered support. This enables managers to have productive peer coaching conversations with other managers and more effective coaching, feedback, performance and career development conversations with their team members.
- MakeSense Technology — MakeSense is a team of tech experts, empowering people who are blind or have low vision.
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Big Data
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Round size: Seed $458k–$3.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 114
- Round size: Seed $150k–$18M; Series A $5.8M–$36M; Series B $19M–$120M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Key AI — Unlock new networking and career opportunities with Key, the leading AI-powered professional networking platform. Build and manage communities, host and join exclusive events, and create meaningful connections to supercharge your growth all in one place.
- OrgOrg — OrgOrg provides internal SaaS tools for organizational productivity suite for the companies
- Odyssey — Odyssey operates as an AI start-up, provides hollywood-grade visual AI.
Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 54
- Round size: Seed $150k–$6.7M; Pre-Seed $110k–$1.5M; Series A $13M–$55M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Replit — Replit is a simple yet powerful online IDE, Editor, Compiler, Interpreter, and REPL. Code, compile, run, and host in 50+ programming languages.
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Ian Hogarth is based out of London, England, and is the Chairman of Phasecraft. Ian previously worked at Songkick as a Chairman. Ian Hogarth attended the University of Cambridge.
Show more...Investment focus
- Industry: Software, E-Commerce, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 55
- Round size: Seed $1.5M–$8.8M; Pre-Seed $668k–$7.7M; Series A $11M–$28M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Blloc — The ultimate smartphone experience. Boost your productivity. Focus on what matters.
- Cordless — Bridging the gap between voice and text
- Heygo — Explore places to visit within the UK and around the world on Rest Less. Get inspired and plan trips to holiday destinations with us.
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 55
- Round size: Seed $1.4M–$4.7M; Angel $190k–$1.3M; Pre-Seed $1M–$2.8M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
- Athens Research — Open-Source Roam Research. A private, extensible, and community-driven knowledge graph.
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: Italy, United Kingdom, France
Investor stats
- Total investments: 17
- Round size: Seed $100k–$45M; Pre-Seed $1.4M–$2.2M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- iubenda — Make your sites & apps legally compliant across multiple languages and legislations (including the GDPR) with our lawyer-crafted, self-updating solutions.
- Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
- Golden — Golden is a developer of a self-constructing knowledge database used to accelerate discovery and education. The company uses and leverages human effort by using machine intelligence to make the process of gathering and communicating knowledge simpler.It combines a powerful search across several entities with fine-grain alerts to stay on top ofchanges, and semi-automatic research assistance for gaps in knowledge that enable people in organizations to stay current, understand and leverage the latest trends in their industry.
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more...Investment focus
- Industry: Health Care, Therapeutics, Biotechnology
- Stage:Angel, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Round size: Angel $150k–$458k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 177
- Round size: Seed $1.1M–$6.8M; Pre-Seed $510k–$5.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skrap — Skrap is an on-demand mobile marketplace for skip hire and other waste collection services.
- Hyphen SCS — Find and rent verified warehouses across 992+ cities in India. Compare 65,000+ listings on Hyphen SCS.
- Interface — Interface is an AI-native Document Management System for High Hazard Industries.
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more...Investment focus
- Industry: Biotechnology, Machine Learning
- Stage:Seed, Convertible Note
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Jeff Dean is the Chief Scientist of Google DeepMind and Google Research. He joined Google in 1999 and has played a pivotal role in shaping the company’s technical foundations. He currently focuses on advancing AI and deep learning research across Google’s research teams.He co-founded and led the Google Brain team, helping drive innovations indeep learning for speech recognition, computer vision, natural language understanding, and a wide range of predictive applications. Over the years, he has co-designed and implemented several generations of Google's core systems, including its web search infrastructure, crawling and indexing pipelines, and advertising technologies such as AdSense for Content.He is also a key contributor to Google's distributed computing infrastructure, having co-designed and implemented systems like MapReduce, BigTable, Spanner, Protocol Buffers, LevelDB, and TensorFlow—one of the most widely used open-source machine learning platforms.Jeff Dean earned his Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the ACM-Infosys Foundation Award in the Computing Sciences and the Mark Weiser Award.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Japan
Investor stats
- Total investments: 87
- Round size: Seed $2.3M–$35M; Pre-Seed $450k–$3M; Series A $6.1M–$53M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Altara — Altara is a San Francisco–based startup building a scientific-intelligence AI platform that analyzes complex physical-science and engineering data (batteries, chips, materials, etc.) to speed up R&D and failure analysis.
- Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
- depthfirst — An AI-native security platform that understands your code, business logic, and infrastructure to find more vulnerabilities, slash false positives, and give developers actionable fixes in their workflow.
Serge Chiaramonte
Show more...Investment focus
- Industry: FinTech, Financial Services, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 57
- Round size: Seed $1.2M–$5.3M; Pre-Seed $637k–$38M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
- qomodo — Qomodo: La piattaforma BNPL innovativa. Rate a tasso zero, approvazioni veloci, transazioni sicure. Rivoluzionaria nell'acquisto per aziende e consumatori.
- Tranched — Introducing real-time on-chain securitisation. Fintech Lenders and Professional Investors can now launch an institutional-grade transaction up to 90% faster than before.
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more...Investment focus
- Industry: Analytics, Cyber Security, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Croatia
Investor stats
- Total investments: 8
- Round size: Seed $1.2M–$5.5M; Pre-Seed $982k–$1.2M; Series A $12M–$12M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Mindflow — Mindflow is a No-Code & Agentic Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks and to deploy AI Agents at scale.
- ESPROFILER — ESPROFILER uniquely combines security spend, commercials, and capabilities with threats helping security leaders maximise their investments.
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 138
- Round size: Seed $500k–$9.3M; Pre-Seed $100k–$3.3M; Series A $4M–$31M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- ToolBelt — The only platform built specifically for licensed pros in residential construction looking for work or finding labor.
- Scaler — Scaler empowers real estate managers to protect investments, reduce operational costs, and meet reporting obligations. Our best-in-class tech delivers faster decisions, smarter strategies, and audit-ready documentation across your entire real estate portfolio
- OneImaging — OneImaging makes life-saving diagnostics affordable, accessible, and personal. We connect employers, health plans, and members to a trusted national network of imaging centers, delivering faster answers with transparent pricing and premium care across MRIs, CT scans, ultrasounds, mammograms, X-rays and more. We serve organizations looking to control medical spend and individuals who need reliable results without delays. Every scan booked through OneImaging is proof that healthcare can be simpler, cheaper, and kinder.
Nadav Ben-Chanoch
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 169
- Round size: Seed $329k–$5.5M; Pre-Seed $125k–$2.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Swaap — We we build & operate onchain trading systems.
- micro1 — We help companies hire and manage the best software engineers easily.
- Dotfile — Dotfile is the Compliance Orchestration Platform for Fintechs. Streamline KYC & KYB and scale AML/CFT due diligences over +200 countries.
Aidan Gomez is based out of Toronto, Ontario and is the co-founder & CEO at Cohere. Aidan Gomez attended the University of Oxford.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 17
- Round size: Seed $2.4M–$12M; Pre-Seed $1.8M–$3.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Extropic AI — The next era of computing isn't dead. It's alive. More coming soon.
- Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
- Helical — The full power of DNA & (m)RNA Bio Foundation Models in one open-core platform. Accelerate Drug Discovery with AI.
Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
Show more...Investment focus
- Industry: Software, E-Commerce, Health Care
- Stage:Series A, Seed, Series C
- Geography: United Kingdom, United States, The Netherlands
Investor stats
- Total investments: 35
- Round size: Seed $1.4M–$8M; Series A $3.2M–$24M; Series C $8M–$24M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- 8fit — Get personalized workouts, custom meal plans, and nutrition guidance, right in the palm of your hand. Prioritize progress over perfection with the 8fit app!
- Ufonia — Dora is a clinical AI agent that calls and supports your cataract patients, empowering your ophthalmology practice to scale without compromise on care.
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Gilad Engel
Show more...Investment focus
- Industry: Hardware, Analytics, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: France, Israel, United Kingdom
Investor stats
- Total investments: 4
- Round size: Seed $1.2M–$1.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Fourier Optics — Fourier optics creates meta-surface based optical systems for Augmented Reality glasses
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Hugh Grant is President and Chief Executive Officer at Monsanto.
Show more...Investment focus
- Industry: Biotechnology, Machine Learning
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
In 2010, Nick founded Lightsource Renewable Energy, then just a six-person start-up, which quickly grew over 5 years to become Europe’s largest solar developer and operator and a recognised global leader. In his role as Group CEO, Nick’s dynamic leadership and vision has driven the company to tremendous success and in December 2017, Lightsourceannounced a strategic partnership with BP which has committed aggressively to accelerate the low carbon transition. The company has rebranded to Lightsource BP in affirmation of this powerhouse commitment which is set to shape the future of global energy delivery. Nick previously sat at Board and Senior Director level in a number of leading retail financial service companies. Throughout his career, Nick has always been recognised for his entrepreneurial skill and success in pairing retail financial products with low-risk, predictable investments.
Show more...Investment focus
- Industry: Biofuel, Agriculture, Artificial Intelligence
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Round size: Seed $3M–$3M
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
Patrick Pichette is based out of London, England, and is the Partner of Inovia Capital and also Board Member of Cohere. Patrick Pichette previously worked at Twitter as a Board of Directors. Patrick Pichette attended the University of Oxford.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 21
- Round size: Seed $750k–$10M; Series A $10M–$95M; Series B $15M–$95M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Kaedim — AI-powered 3D asset creation service delivering fast, production-ready 3D assets. Scale 3D pipelines without hiring, accelerate 3D game art production, and reduce 3D asset costs by up to 90%.
- Apheris — Superior drug discovery models through federated data networks
- made of air — Made of Air is a carbon-negative materials company. They take low-value wood waste and transform it into high-value, carbon-negative thermoplastics. These thermoplastics can be formed with all traditional heat-forming methods and used for a wide variety of applications, turning manufactured goods into engineered carbon sinks.
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Health Care
- Stage:Series A, Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 29
- Lead/follow: no public data
Portfolio highlights
- Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Amar Shah is based out of London and is the Founder & Partner of Dhyan VC. Amar previously worked at Firstminute Capital as an Entrepreneur In Residence. Amar Shah attended the University of Cambridge.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Pre-Seed, Seed, Angel
- Geography: United Kingdom, Poland, Germany
Investor stats
- Total investments: 10
- Round size: Seed $4.8M–$15M; Pre-Seed $642k–$2.8M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- TextCortex — Create the highest quality content 7x faster, using TextCortex AI - the best copywriting tool for all your content. Get started for free, no credit card required.
- PHINXT Robotics — PHINXT Robotics enables warehouses of any size to deploy autonomous robots as needed, with no expertise required.
- Martian Lawyers Club — Home of GUG and Nomic
Paul Forster is an early-stage investor in the tech sector. He previously worked at Indeed as a Senior Advisor. Paul attended INSEAD, where he earned an MBA.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 78
- Round size: Seed $1.1M–$7.2M; Pre-Seed $1.1M–$3.5M; Series A $3.9M–$15M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Oraion — Your single source of truth for enterprise data
- Stackfix — Stackfix operates as a software comparison platform.
- Kombo — One unified API for HRIS, Payroll & ATS
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more...Investment focus
- Industry: Software, SaaS, Financial Services
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 16
- Round size: Seed $962k–$2.5M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Lunio — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
- Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
- PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
Chris Mairs - Venture Partner @ Entrepreneurs First
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Pre-Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 25
- Round size: Seed $655k–$3.9M; Angel $334k–$707k; Pre-Seed $917k–$2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- nMachine — A Low-Code solution for creating extraordinary Day 2 Operations platforms - called nMachines - for your existing Kubernetes-based applications, that can be shared inside and outside your organization.
- Incard — Welcome to the world's first payment solution designed exclusively for e-commerce, entrepreneurs, dropshippers and influencers. Join our waitlist now.
- Tuza — Find the right card machine for your business, with good rates and the best features. Search the top providers in minutes, including Worldpay, Barclaycard, Tyl and Teya.
Ed Parkinson
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Round size: Seed $1.8M–$3.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
Edward Lando is the founder of Pareto Holdings. He previously worked at Horizons School of Technology as a co-founder. Edward Lando attended the Wharton School.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 314
- Round size: Seed $500k–$6.6M; Pre-Seed $125k–$3.3M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Swaive — Swaive operates a financial firm that invests in risk-free instruments. The organization allows you to park your money without risk.
- AstroForge — We mine asteroids to extract valuable minerals in space at a lower cost and smaller carbon footprint than the current terrestrial mining methods.
- Autoplay — Autoplay is an AI-powered platform that improves digital adoption by offering real-time, context-aware guidance. It learns from user interactions and software interfaces, adapting to help enterprises optimize usage, streamline workflows, and boost engagement across teams.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more...Investment focus
- Industry: FinTech, E-Commerce, Financial Services
- Stage:Seed, Angel, Pre-Seed
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Seed $500k–$8.5M; Angel $233k–$1M; Pre-Seed $1.2M–$2M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Ukio — Artfully designed fully furnished apartments available for extended stays
- Paack — Online sales growth and customer satisfaction are hampered by inadequate delivery experiences. Existing last mile delivery companies are incapable of providing a truly customer-centric approach. Our proprietary technology stack and operational excellence is built specifically to service time slot deliveries, controlled entirely by the endcustomer. This creates unprecedented results through basket conversion, loyalty, repeat purchase, acquisition, brand image and customer satisfaction, plus they can actually help the environment.Paack operates in Europe (UK, France, Spain and Portugal).
- Solid Financial Technologies, Inc — Instantly create bank accounts, send payments and issue cards, powered by the Solid Platform. Embedded Banking. Banking as a Service (BaaS) | Payments as a Service | Cards as a Service | Compliance as a Service
Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.
Show more...Investment focus
- Industry: Software, Social Media, Internet
- Stage:Seed, Series A, Angel
- Geography: United States, Spain, Mexico
Investor stats
- Total investments: 45
- Round size: Seed $455k–$7M; Angel $1M–$1.7M; Series A $3M–$7.9M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Goin — Goin is a mobile application to save money easily and take advantage of it without knowing how to invest, through Machine Learning algorithms that allow you to accumulate the user's money through small daily gestures. he three Spanish founders, David, Carlos and Gabriel, were looking for a way to optimize their own money, and decided toconduct an experiment by exchanging their debit cards and thus saving 62% during those two months of rehearsal. This is how Goin emerged, which aims to meet the needs of 100% of Millennials, of which 83% confess that they do not know how to save, making available an easy-to-use tool that enhances their finances and lifestyle. On the one hand, the Barcelona startup allows the user to add money automatically and multiply it without having previous knowledge of investment. Goin uses a simple system that first asks to know the user through questions about their habits and, in this way, they are offered automatic systems and methods of saving. Once the user adds money to the app, they can transfer part or all of it to investment, or to their bank account. Its Smart Saving technology manages to accumulate money with small, everyday gestures, such as rounding a payment.
- Kiwibot — Delivery robots to optimize your business and deliver safely and timely to your customers.
- Grin Scooters — Grin Scooters is a software company that operates network of operational shared electric scooters. Currently, Grin only operates in Mexico City, Guadalajara, Monterrey, Sao Paulo and Bogota but it has plans to expand to other cities throughout Latin America.
Mati Staniszewski is the Co-Founder of ElevenLabs.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Poland
Investor stats
- Total investments: 12
- Round size: Seed $5M–$10M; Pre-Seed $2M–$5M; Series A $16M–$40M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- CodeWords —
- VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
- Elastics — Elastics is an AI-native operating system for prediction markets and beyond. Powered by auditable AI agents, it allows traders to build and automate trading workflows in plain language, from signal generation to live execution.
Robert Kopple
Show more...Investment focus
- Industry: FinTech, Finance, Life Science
- Stage:Convertible Note
- Geography: United States, United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Tradier — Tradier is a financial services cloud provider that offers a groundbreaking solution to serve platform providers, developers and investors. The Tradier solution features an innovative set of fully hosted APIs, modules, and "out of the box" tools that are leveraged by a growing list of providers.
- ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.
Damien Lane has spent the last 20 years investing in private companies, both in Private Equity where he was a partner with Electra Partners, then at Octopus Ventures where he was a senior member of the investment team. Having made a number of angel investments, Damien co-founded Episode 1 with Simon and Adrian in 2012. While at Episode 1,Damien has led investments in Carwow, Scurri, Touch Surgery, Attest and Zipcube and loves working with early stage teams of entrepreneurs; helping them develop their early stage startup into a fast growth enterprises capable of raising more funding from later stage investors. When he is not trying to help businesses to implement an optimal approach to growth, Damien can mostly be found running around Hampstead Heath or the Coastal paths of Great Britain. Having trained obsessively to run a 2:52 Marathon in 2015, he is now trying to dip below 2:50, in the spirit of continuous improvement. Damien has an MBA from Cambridge University and a Masters degree in PE from Oxford University.
Show more...Investment focus
- Industry: SaaS, Software, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 38
- Round size: Seed $459k–$3.1M; Pre-Seed $605k–$1M; Series A $3.2M–$16M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Calira — Calira (formerly Clustermarket). Give researchers an easy way to book equipment, improve equipment utilisation, and get structured lab usage data.
- Realla — Search the entire commercial property market for offices, serviced office space, retail, industrial for sale and to rent
- IVO — Platform to allow media owners to deepen advertiser engagement, increase profitability and commercialise ad solutions with ease.
Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.
Show more...Investment focus
- Industry: Biotechnology, Health Care, AgTech
- Stage:Seed, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 10
- Lead/follow: no public data
Portfolio highlights
- twig bio — twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
- Resurrect Bio — Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Jim started work at Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim then joined Abcam as a Technical Director, and took over the operational management of the UK office as Managing Director in June 2004, working on both cost saving and efficiency improvementprojects. In 2009, Jim became Chief Operating Officer, with the responsibility for overseeing the operational strategy of the Group. Jim is a Director of Chesterton Community College, Chesterton Sports Centre Limited and Cambridge Nutraceuticals Limited. He has also taken up a non-executive position at Quartix Holdings Plc. Jim had over 15 years’ experience in developing and implementing IT systems and strategy before moving into a broader operational management role within Abcam.Here his skills have been particularly focused on developing a scalable operating model for Abcam which, supported by IT systems, has underpinned Abcam’s rapid growth over the past decade.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team
Siddhant Jayakumar
Show more...Investment focus
- Industry: Biotechnology, Public Safety, Artificial Intelligence
- Stage:Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- sable bio — We provide comprehensive, quantified, and flexible Target Safety Intelligence to assist toxicologists, informaticians, and drug discovery scientists in delivering safe and effective new treatments.
Andrew Richards is an established biotechnology entrepreneur and investor with extensive experience from the UK biotechnology sector in research, drug development, commercial deals and scale-up of companies.
Show more...Investment focus
- Industry: Biopharma, Education, Biotechnology
- Stage:Post-IPO Equity
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Jan Hruska
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Margaret Georgiadis is the Co-founder and CEO of Montai Therapeutics. Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University.
Show more...Investment focus
- Industry: Health Care, Apps, Wellness
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom
Investor stats
- Total investments: 15
- Lead/follow: no public data
Portfolio highlights
- OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
- ShareWell — Struggling with mental health? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
- Bridge Money — The path towards upward economic mobility.
Silla Scheepens of Future Food Fund.
Show more...Investment focus
- Industry: Biotechnology, Food Processing, Food and Beverage
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Extracellular — Extracellular is a scale-up and development partner, channelling biology, digitalisation and biomanufacturing expertise to accelerate the potential of cultivated meat.
Fiona is Managing Partner at Crista Galli Ventures, an early stage healthtech VC fund based in London and Copenhagen.
Show more...Investment focus
- Industry: Health Care, Science/Engineering, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Germany, Armenia
Investor stats
- Total investments: 9
- Lead/follow: no public data
Portfolio highlights
- Daye — Organic, super absorbent, sustainable tampons for when your period is cramping your style. ProViotics for vaginal health. We deliver sustainable products that work hard to help you feel your best, whatever life brings.
- Melon — Save & organise content from any source. Follow experts and friends. Share your knowledge with others.
- Holly Health — Rebuild your relationship with food and manage your stress with Holly Health, your personalised health coach.
Declan Doogan has over 30 years of industry experience in both major pharma and biotech.He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Sinceleaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo).Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Science/Engineering
- Stage:Seed, Series A
- Geography: United States, United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Causeway Therapeutics — A bio pharmaceutical spin out emerging from the University of Glasgow, working in the orthobiologic therapeutic space. Intellectual property has been generated via academic research demonstrating a proven mechanistic reasoning for the use of a microRNA therapy in the treatment of tendinopathies.
- Intensity Therapeutics — Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.
Ahmed Medhat - Research Scientist, Core Data Science @ Meta
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Machine Learning
- Stage:Seed, Pre-Seed
- Geography: United States, United Kingdom
Investor stats
- Total investments: 8
- Lead/follow: no public data
Portfolio highlights
- Ntropy Network — Unlock the power of transactions. Our technology enables flexible and autonomous banking data cleansing, labeling and enhancement.
- Grin Gaming — GrinData micro markets software leverages best-in-class high-frequency trading and machine learning to deliver reliable odds pricing on the most markets.
- Anarchy — Anarchy builds a cloud platform for AI pioneers to build LLM tools augmented with external interactivity.
Christopher Emmanuel Paul is an American professional basketball player for the Oklahoma City Thunder of the National Basketball Association.
Show more...Investment focus
- Industry: Food and Beverage, Sports, Health Care
- Stage:Seed, Series A
- Geography: United States, France, Portugal
Investor stats
- Total investments: 19
- Lead/follow: no public data
Portfolio highlights
- Scout - Make Money Moves — Scout is the financial wellness platform for student athletes in the new NIL era. We empower athletes to make better financial decisions with live financial education sessions and personalized, tech-enabled service.
- Buoy — Zero sugar liquid electrolytes and ionic trace minerals that blend with any beverage, even alcohol and coffee. No sugar, no stevia, no dextrose, no flavorings and no artificial ingredients. Gluten and major allergen free. Vegan and non-GMO.
- Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
Marcus East is an international technology and product executive and CDO/CIO/CTO with over 25 years experience of working in the Information Technology, specializing in, Digital Product, Digital Transformations and Electronic Commerce. He has two degrees: a Bachelor’s with honors in Management & Information Technology (Modular) fromLondon Guildhall and a Master’s in Management from the University of Cambridge. He is also a full member of the Chartered Management Institute, a Fellow of the British Computer Society Chartered Institute for IT, and holds the IoD Certificate in Company Direction. Marcus started his career with IBM where he spent six years honing his consulting and strategy skills, before joining Omnicom’s agency.com where he spent two years learning about the importance of user experience, and further developed his management skills. Since then, he has held senior digital leadership positions for a number of major brands, including Comic Relief, Apple and National Geographic.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- OxCan — Enabling curative cancer treatment through early detection
Sam Fazeli is the Non Executive Director at Arecor Limited.
Show more...Investment focus
- Industry: Education, Health Care, Biotechnology
- Stage:Post-IPO Equity
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Johnathan Matlock is Co-Founder Science Angel Syndicate.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- MintNeuro — MintNeuro is pioneering the use of semiconductor technology in next-generation neural implants.
- Argonaute RNA — Developing safe and reliable methods of temporarily silencing target genes in different tissue cells.
- Halo Therapeutics — Halo Therapeutics is based in England. Develops safe pan coronavirus antiviral drugs for Covid-19 that can be administered by patients.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Angel Investors in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 angel investors investing in United Kingdom Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!